GlassScriptPhysician profile
Sandra Cremers
NPI 1588654040
$6,077.22
in general payments reported to CMS, 2019-2025
35 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $793 · 2021: $635 · 2022: $536 · 2023: $1,670 · 2024: $828 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,514 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,513.72 |
| Education | $105.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,397.67 | 2020-2025 | Acthar |
| Alcon Vision LLC | $692.81 | 2019-2025 | Clareon, Argos, Hydrus Microstent |
| Allergan, INC. | $616.80 | 2019-2021 | |
| New World Medical,INC. | $404.86 | 2023 | |
| Rxsight INC | $288.21 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Oyster Point Pharma, INC. | $282.36 | 2022-2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $244.36 | 2019-2025 | Cequa |
| Abbvie INC. | $234.59 | 2022-2024 | Durysta, Lumigan, Vuity |
| Sight Sciences, INC. | $200.15 | 2019-2025 | Omni Surgical System |
| Amgen INC. | $186.27 | 2024-2025 | Tepezza |
| Glaukos Corporation | $135.72 | 2022-2025 | Idosetr |
| Genentech USA, INC. | $126.88 | 2025 | Susvimo |
| Tearlab Corp | $120.84 | 2020 | |
| Biotissue Holdings INC. | $115.63 | 2020-2025 | |
| Tarsus Pharmaceuticals, INC. | $103.82 | 2024-2025 | Xdemvy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $101.81 | 2019-2024 | Oxervate |
| Mallinckrodt Enterprises LLC | $96.74 | 2019 | |
| Kala Pharmaceuticals, INC. | $91.73 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $87.91 | 2020-2023 | |
| Bausch & Lomb Americas INC. | $86.10 | 2023-2024 | Miebo, Xiidra |
| Johnson & Johnson Surgical Vision, INC. | $72.41 | 2019-2023 | Tecnis Iol |
| Aerie Pharmaceuticals, INC. | $56.97 | 2020-2021 | |
| Harrow Eye, LLC | $42.72 | 2025 | Vevye |
| Shire North American Group INC | $38.10 | 2019 | |
| Ocular Therapeutix, INC. | $32.60 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $30.36 | 2020 | |
| Rayner Intraocular Lenses Limited | $29.44 | 2023 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Ani Pharmaceuticals, INC. | $26.46 | 2025 | Purified Cortrophin Gel |
| Ivantis, INC | $24.28 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $23.99 | 2021 | |
| Boston Scientific Corporation | $23.34 | 2019 | |
| Spark Therapeutics, INC. | $20.46 | 2021 | |
| Eyevance Pharmaceuticals LLC | $14.62 | 2020 | |
| Alcon Research LLC | $14.36 | 2019 | |
| Oasis Medical, INC. | $11.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Cremers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.